You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Mallinckrodt
Harvard Business School
Dow
Johnson and Johnson

Last Updated: April 6, 2020

DrugPatentWatch Database Preview

XPOVIO Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Xpovio, and what generic alternatives are available?

Xpovio is a drug marketed by Karyopharm Theraps and is included in one NDA. There are three patents protecting this drug.

This drug has seventy-two patent family members in thirty-one countries.

The generic ingredient in XPOVIO is selinexor. One supplier is listed for this compound. Additional details are available on the selinexor profile page.

US ANDA Litigation and Generic Entry Outlook for Xpovio

Xpovio will be eligible for patent challenges on July 3, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 15, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for XPOVIO
International Patents:72
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 24
Patent Applications: 13
Drug Prices: Drug price information for XPOVIO
DailyMed Link:XPOVIO at DailyMed
Drug patent expirations by year for XPOVIO
Drug Prices for XPOVIO

See drug prices for XPOVIO

Generic Entry Opportunity Date for XPOVIO
Generic Entry Date for XPOVIO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for XPOVIO
(2Z)-2-(2-Pyrazinyl)hydrazide-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]-2-propenoic acid
(Z)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide
(Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-N'-pyrazin-2-ylprop-2-enehydrazide
1393477-72-9
2-Propenoic acid, 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-, 2-(2-pyrazinyl)hydrazide, (2Z)-
2-Propenoic acid, 3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]-, 2-(2-pyrazinyl)hydrazide, (2Z)-
2500AH
31TZ62FO8F
A12582
CHEMBL3545185
compound 70 [WO2013019561A1]
D11222
DB11942
DEVSOMFAQLZNKR-RJRFIUFISA-N
EX-A870
GTPL10036
J-690156
KPT 330
KPT-330
KPT-330(Selinexor)
KPT330;Selinexor
MFCD27987944
N-Hydroxy-N'-(2-phenylethyl)isophthalamide
NCGC00386310-03
S7252
SCHEMBL14678327
Selinexor
Selinexor (KPT-330)
Selinexor (USAN/INN)
Selinexor [USAN:INN]
SW219336-1
Tube706
UNII-31TZ62FO8F
ZINC96170454

US Patents and Regulatory Information for XPOVIO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-001 Jul 3, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-001 Jul 3, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-001 Jul 3, 2019 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Mallinckrodt
Harvard Business School
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.